NCT00423670View on ClinicalTrials.gov

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

PHASE2CompletedINTERVENTIONAL

Enrollment

765

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

November 30, 2008

Conditions

Chronic Hepatitis C

Interventions

DRUG

boceprevir (SCH 503034)

200 mg capsules taken as 800 mg orally three times daily (TID)

DRUG

peginterferon-alfa 2b (PegIntron)

1.5 μg/kg subcutaneously (SC) once weekly (QW)

DRUG

ribavirin

200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily

DRUG

ribavirin (low-dose)

200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00423670 - Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) | Biotech Hunter | Biotech Hunter